Emcure Pharmaceuticals Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹300(29.76%)
Premium (ELP)
Emcure Pharmaceuticals Limited's completed its IPO journey with a successful listing on NSE, BSE on Jul 10, 2024. The public offering mobilized 1,93,65,347 Shares in total capital, comprising 79,46,231 Shares in fresh equity and ₹1151.45 Cr in Offer for Sale shares from existing stakeholders.
The offering was conducted within the price band of ₹960 to ₹1,008, with minimum application lots of 14 shares. Investor participation during the Jul 03, 2024 to Jul 05, 2024 subscription window determined the final allocation pattern.
The basis of allotment was announced on Jul 08, 2024, finalizing share distribution to successful applicants. The listing represents a significant corporate development, providing the company with enhanced visibility and access to public capital markets.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Emcure Pharmaceuticals Limited, incorporated in 1981, is a leading Indian pharmaceutical company engaged in the development, manufacturing, and global marketing of a diverse range of pharmaceutical products across multiple therapeutic areas. Ranked 13th in domestic sales and 4th in market share in covered markets for MAT September 2023, Emcure is a leader in the gynaecology and HIV antiviral segments. With domestic sales contributing over 50% of total revenue and growing at a CAGR of 10.80% between September 2019 and September 2023, the company has outpaced the Indian pharmaceutical market. It operates five research facilities in India, employing 552 scientists and filing over 1,800 global regulatory documents, including 201 granted patents. Emcure's 13 manufacturing facilities in India produce a wide range of pharmaceutical and biopharmaceutical products, including chiral molecules, iron molecules, and cytotoxic substances. Supported by over 5,000 field personnel and 5,000 stockists across 37 carry-and-forward agents, the company maintains an extensive marketing and distribution network, ensuring strong engagement with healthcare providers and efficient product availability.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Strong Domestic Market Presence: The company is strategically positioned to capitalize on its established foothold in the domestic market.
- Proven Brand Development Expertise: A track record of successfully building and strengthening brand identity, enhancing market recognition.
- Expanding Global Portfolio: A rapidly growing and diverse product range catering to international markets, driving global business growth.
- Manufacturing and Quality Risks: Any lapses in manufacturing processes or quality control could harm the company's reputation, invite regulatory scrutiny, and lead to potential legal liabilities.
- Quality Standard Compliance: Non-compliance with industry quality standards may result in product liability claims, affecting financial stability and operational efficiency.
- Supply Chain Vulnerabilities: Dependence on outsourced raw materials and finished goods exposes the company to risks of supply chain disruptions and cost fluctuations, potentially impacting pricing, profitability, and overall business performance.
- Satish Mehta
- Sunil Mehta
Emcure Pharmaceuticals Limited
Link Intime India Private Limited